Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Microbiome Medics

Microbiome Medics artwork

Beyond the Gut: The Surprising Science of Respiratory Microbes with Dr. Michael Cox

May 13, 20261 hr 1 minAudio
ShareXLinkedInFacebookWhatsAppEmail

While the gut microbiome often steals the spotlight, the microorganisms residing in our respiratory tract play a vital role in our health and immunity. In this episode, Dr. Sheena Fraser sits down with microbial ecologist Dr. Michael Cox to explore the fascinating, complex, and relatively uncharted territory of the lung microbiome. They discuss how the lung microbiome fundamentally differs from the gut, the daily flux of bacteria entering and leaving our airways, and the profound impacts of environmental factors like air pollution, smoking, vaping, and household cleaning products. Plus, Dr. Cox shares the massive challenges scientists face when studying these deep-tissue microbes and what the future of respiratory medicine might look like. What We Cover: From Seawater to Sputum: Using marine ecology techniques to decode human respiratory biology. Exploring the lungs' dynamic balance of microaspiration and mucociliary clearance. Meet the core lung bacteria (Streptococcus, Prevotella, Veillonella) and the puzzle of anaerobes in an oxygen-rich space. Environmental Disruptors: How pollution, smoking, and vaping inflame and alter the lung microbiome. Hidden Dangers of VOCs: The silent impact of everyday cleaning sprays and aerosols on respiratory health. Diet, Exercise, & Epigenetics: The systemic benefits of a high-fiber diet and fitness for chronic lung conditions like COPD and asthma. About Dr. Michael Cox is a microbial ecologist and the PGR Lead for the Institute of Microbiology and Infection at the University of Birmingham. His research focuses on the bacteria that reside in the respiratory tract in the context of respiratory diseases (such as COPD and Cystic Fibrosis). His lab works to understand the function of the respiratory microbiome, translate these findings for clinical benefit, and expand our understanding of the respiratory ecosystem beyond just bacteria. Connect with Dr Michael Cox: University of Birmingham Scientific References & Further Reading: Cumming, K. J. (2018). "Long term effects of cleaning on the lungs." American Journal of Respiratory and Critical Care Medicine, 197(9):1099-1101. Hussain, S., et al. (2024). "Unlocking the secrets: VOCs and their devastating effects on lung cancer." Pathology - Research and Practice, 255:155157. Welsh, H. A., et al. (2026). "The effect of vaping on the human lung microbiota." Inhalation Toxicology, Vol 38, Iss 1. This podcast is brought to you in collaboration with the British Society of Lifestyle Medicine. Disclaimer: The content in this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or qualified healthcare provider. Never disregard professional medical advice or delay in seeking it because of something you have heard on this podcast.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

Intro and Outro: Hello, and welcome to the Microbiome Medics Podcast. Intro and Outro: I'm Dr. Siobhan McCormack. And I'm Dr. Sheena Fraser, and we're your co-hosts. Intro and Outro: We are both GPs and lifestyle medics with a shared passion for microbiome science. Intro and Outro: We'll be translating the evidence and packaging it into actionable, Intro and Outro: bite-sized chunks so that you could harness the power of the microbiome to improve Intro and Outro: your own health and that of your patients. Sheena Fraser: Hello, and welcome to another Microbiomedics podcast. I'm Dr.

Sheena Fraser: Sheena Fraser, and today I'm joined with Dr. Michael Cox. Sheena Fraser: Dr. Michael Cox is going to introduce us to the lung microbiome today. Sheena Fraser: So we've already had a little intro into the vaginal microbiome, the skin microbiome. Sheena Fraser: We've obviously touched a lot on the gut microbiome. Sheena Fraser: So today I'm really excited to delve into the lung microbiome. Sheena Fraser: Dr. Cox is based in Birmingham, and his research focuses on microbial ecology Sheena Fraser: of the respiratory tract. Sheena Fraser: And he's translating the microbial analysis of the respiratory tract into clinical,

Sheena Fraser: useful, knowledgeable information for our clinicians. Sheena Fraser: So today, let's have a little chat. Sheena Fraser: We're going to touch on what the lung microbiome is. We're going to take you Sheena Fraser: through the importance and the correlation between the lung microbiome and the Sheena Fraser: gut microbiome, and also the communication between the two, Sheena Fraser: and then translation into the clinical side, Sheena Fraser: you know, how this impacts on our health, how it impacts on disease, Sheena Fraser: and go through from there. So thanks, Mike.

Sheena Fraser: Thanks for joining me today. Welcome to the podcast. Michael Cox: Thanks. Sheena Fraser: Yeah. Tell me a little bit more. So I'd like, what I'd like to really start Sheena Fraser: with is first of all, how did you get into studying the lung microbiome? Sheena Fraser: Cause there's not that many of you around. Michael Cox: It's not, we're a weird bunch. Yeah. Michael Cox: So my route was a sort of, essentially a sort of field change really. Michael Cox: So I started out studying seawater microbial ecology. So communities of bacteria Michael Cox: in seawater and their impact on climate and particularly the ozone layer at

Michael Cox: the time, and how they use trace gases. Michael Cox: So sort of interactions between bacteria and their environment. Michael Cox: And then around 2008, I took up a position at the University of California, Michael Cox: San Francisco, and the techniques we were using in the environmental field were Michael Cox: suddenly starting to gain a bit of traction in the human microbiome field or in human research. Michael Cox: And I got the opportunity to study people with cystic fibrosis,

Michael Cox: or at least the samples from people with cystic fibrosis, which has always been Michael Cox: known as a sort of polymicrobial infection in the lungs, this chronic lung disease. Michael Cox: So it was really a techniques-based thing. Michael Cox: So rather than a bucket of seawater that I was studying and the interactions Michael Cox: with its environment, I was studying a bucket of sputum instead. Michael Cox: Nothing. Yeah, I mean, this is the field. Michael Cox: It's a lot of sputum is what we end up with in the lung microbiome field.

Michael Cox: So yeah, I came following the techniques really across in that route. Michael Cox: And then that's expanded to other diseases and healthy lungs over the course of my research. Sheena Fraser: Lovely. Okay. So let's think about the lung microbiome. Sheena Fraser: And I'm really interested in Sheena Fraser: how the lung microbiome compares to the gut microbiome and how it differs. Sheena Fraser: So can you give us a little bit of an info on that? Michael Cox: So I think, I mean, it's quite different.

Michael Cox: The key thing is that as a site, we're constantly clearing our lungs. Michael Cox: So we've got the mucosiliary escalator. We've got sort of rafts of mucus. Michael Cox: And that's designed to keep things coming out. Michael Cox: But we do also have a constant flow of stuff going in as well. Michael Cox: So we've got sort of microaspiration from saliva. Michael Cox: We might have bits of the oral microbiome and the nasal microbiome traveling Michael Cox: down into the lungs. And that's normal.

Michael Cox: So probably there's quite a bit of micro aspiration that goes on overnight. Michael Cox: So it's more of a balance between these two processes of clearance and deposition, Michael Cox: at least in healthy people. Michael Cox: So the numbers of bacteria that are there are much, much lower than you see in the gut. Michael Cox: That doesn't necessarily mean they're not doing anything, which I think is super important because. Michael Cox: Quite low numbers of bacteria can have quite an impact biologically because

Michael Cox: they do all sorts of unique things that human cells don't do. Michael Cox: So it's this sort of balance, this equilibrium between what goes down and what comes up. Michael Cox: We have only the one hole in the lungs as opposed to two. You know, Michael Cox: it's not the donut of the gut. Michael Cox: So, clearance is a slightly different process. Michael Cox: But yeah, numbers are different. Composition is a little bit different as well. Michael Cox: So, the most common organisms we find there are quite different to the most

Michael Cox: common organisms that you'd measure in the gut microbiome. Michael Cox: So, the sort of top favorites are things like Streptococcus, Michael Cox: Prevotella and Violonella, which you can find in the gut, but not at the same abundances. Michael Cox: So those top three are the most abundant organisms in everyone. Sheena Fraser: And are those organisms, they're Sheena Fraser: aerobes, so organisms that like a bit of air, or are they anaerobes? Michael Cox: Yeah, they're weird. So what we find actually is usually you would consider

Michael Cox: microbiologically, pre-vitella and violin anaerobes in particular, to be strict anaerobes. Michael Cox: They're quite hard to isolate aerobically. you'd have to usually use an anaerobic cabinet to grow them. Michael Cox: But we find they're the most common organisms alongside Streptococcus. Michael Cox: And I think that's sort of explainable by, Michael Cox: I mean, the lung surface is probably enriched in CO2, about 5% CO2. Michael Cox: If you measure right at the lung surface, you've probably got less oxygen than,

Michael Cox: you know, in ambient air. Michael Cox: So maybe these organisms, we could consider them microaerophilic. Michael Cox: That's a sort of microbiology term for this kind of state, where they perhaps Michael Cox: can tolerate a little more oxygen than their sort of strict anaerobic expectations of these bugs. Michael Cox: But, yeah, it's sort of counterintuitive that an organism designed for use of Michael Cox: oxygen at the surface has these anaerobic organisms. Sheena Fraser: Interesting. Okay. And so they're similar in that there is a flux of organisms.

Michael Cox: Yes. Sheena Fraser: But obviously in the lungs, that flux goes down and then back up. Sheena Fraser: And then in the gut, obviously, it goes out and then is expelled out the other end. Sheena Fraser: Okay. And then with the microorganisms in the lung, obviously you've got fewer of them. Sheena Fraser: Is it variable in different parts of the lungs? So, you know, Sheena Fraser: how do the end pieces, the alveoli, Sheena Fraser: the little air sacs right at the very end, how do they compare to the big tubes,

Sheena Fraser: the trachea, the bronchi? Sheena Fraser: How do they compare? Michael Cox: This is really difficult because one of the challenges we have in the lungs is sampling. Sheena Fraser: Yeah. Michael Cox: So we're always sampling, usually through the mouth or nose. Michael Cox: So anything we find is not independent of those two sites usually. Michael Cox: There have been some studies of explanted lungs. Michael Cox: So in people who've had to have lung transplants, then some groups have looked Michael Cox: at the lungs that were taken out.

Michael Cox: And that allows you to sample through the side and to be very careful that you're Michael Cox: not contaminating any part of the lung with any other sort of microbiological source. Michael Cox: And there they can see differences around the lung. Michael Cox: So different parts of the lung might have different bacteria, Michael Cox: different compositions of the microbiome present. Michael Cox: The caveat there is that's always end-stage lung disease because you don't get Michael Cox: a pair of lungs that are good lungs that you don't want to use for a transplant or some other purpose.

Michael Cox: So it's an end-stage disease. So we don't really know, I don't think, Michael Cox: in healthy people about variation like that. Michael Cox: What we can probably say for sure, I think, is the further down the tree you Michael Cox: go in the lungs, the fewer organisms you would expect to see. Michael Cox: I think they do reach the alveoli. So, you know, we have another clearance mechanism Michael Cox: there, the alveolar macrophages that sort of roam around gobbling up bacteria and particles.

Michael Cox: And they wouldn't be there if they didn't have a job to do. Michael Cox: And these sort of sizes of particles reach down there. Michael Cox: But probably there's a gradient of higher numbers at the top in the larger airways Michael Cox: and then fewer in the peripheral airways ways and then fewer still in the alveolar. Sheena Fraser: Okay and you mentioned this flux Sheena Fraser: from the oral microbiome and the nasal microbiome Sheena Fraser: so that all the little microorganisms in the mouse and Sheena Fraser: the nose and how they can travel down

Sheena Fraser: into the lungs and so we're sort Sheena Fraser: of micro aspirating so little just inhaling little pieces of these part of these Sheena Fraser: microbiomes into our lungs all the time and they're they're traveling down so Sheena Fraser: so how does that relationship between the nose and the mouth go and what what Sheena Fraser: is the importance of that would you say. Michael Cox: This is sort of interesting, and I think inhaling as well, because the sources Michael Cox: of the organisms, so Streptococcus violanella prevotella, we certainly find

Michael Cox: in the oral cavity as well. Michael Cox: Those probably not the major organisms in the nasopharynx, in the nasal cavity. Michael Cox: So there are certain things that are unique to these environments as well. Michael Cox: So the nose, you often see things like Delosigranulum and Carinobacterium. Michael Cox: I love some of these names. Michael Cox: Um, but, uh, you know, we don't see those routinely in samples from the lung

Michael Cox: or lower down in the lung. Michael Cox: Um, similarly, there are a lot of organisms that are associated with dentition Michael Cox: with teeth, with sort of cruvicular fluids, that, that fluid that builds up Michael Cox: between your teeth and your gums that are quite unique to that site that we Michael Cox: don't see in the lungs as well. Michael Cox: So there's some process of selection going on here. There are things that are Michael Cox: either easier to get into the lungs... Michael Cox: Or tend to stick around a bit there. Michael Cox: And that's a very hard thing to measure, partly because of how you sample,

Michael Cox: and sampling over time is what you need to do. Michael Cox: But probably there is something like that, because across different people, Michael Cox: we always see those three dominant organisms in health. Michael Cox: There's something about that environment that allows them to be there. Michael Cox: We don't know what that is. Sheena Fraser: Okay, so they're the travelers. Michael Cox: Yes, yeah, I think so. resident Michael Cox: is would be a controversial term because you've got Michael Cox: this process of them moving out we don't even know whether there's growth in Michael Cox: there so in the gut for example it's repopulated because you know that there's

Michael Cox: bacteria definitely growing in in your gut we don't know that whether the ones Michael Cox: in your lungs are actively growing in situ which would add which would shift that balance as well so. Sheena Fraser: Then maybe we should talk about what they're actually doing there um. Michael Cox: Hey that's my that's my job that's that's the million dollar question yeah so. Sheena Fraser: What are these bugs doing in our lungs what what is the purpose. Michael Cox: I mean i just think they're sort of i always like to think of humans as sort Michael Cox: of meat puppets and and i'm i'm i'm all about the bacteria when it comes to

Michael Cox: this but they're just hanging out having a good time i streps probably the streptococcus is, you know, Michael Cox: existing on the mucin that we produce, and that's produced constantly, Michael Cox: and as well as being removed, probably being degraded by the streptococci as well. Michael Cox: I think probably Prevatella and Violonella have roles there as well. Michael Cox: So they're sort of happy grazers. Michael Cox: Positive impacts are sort of hard to show. So, there's a little bit of evidence

Michael Cox: that certain organisms might interact with inflammation. Michael Cox: So there's one called Rothia mucilaginosa that some people have shown in vitro, Michael Cox: at least, in lab experiments. Michael Cox: Some strains of it can impact inflammation. Michael Cox: But this kind of research in the lungs, you know, it's more common to talk about Michael Cox: those kind of interactions in the gut microbiome because it's a tough site to Michael Cox: sample and to understand.

Michael Cox: That research lags in the lungs. So there might be interactions there that sort Michael Cox: of dampen down inflammatory responses, Michael Cox: but there's certainly plenty that increase inflammatory responses because we Michael Cox: know about the sort of lung infection pathogens and stuff. Sheena Fraser: Yeah. And so we know from the oral microbiome as well that they can play a role Sheena Fraser: in your initial fighting off of infections. Sheena Fraser: So, you know, some of the more mucus-dwelling bacteria, they play a role with

Sheena Fraser: IgA, like lactobacillus plays a role with IgA. Are there any lactobacillus in the lungs? Michael Cox: Yeah, you can detect them. We don't know. Again, we don't know what they're doing. Michael Cox: Um, the abundance isn't very high because, so it's a low abundance environment altogether. Michael Cox: And then they're not the most common ones, but you can detect them. Michael Cox: Um, but similarly in the gut, they're not necessarily in the most abundant ones. Michael Cox: I think probably of these kind of sort of, we call them commensals where they're

Michael Cox: not having, where they're there, but we don't know what they're doing and they Michael Cox: might not be having a positive or negative effect. Michael Cox: They might just be sort of hanging out the, Michael Cox: I wonder whether the streps are going to be more, those abundant ones are going Michael Cox: to be more important in terms of interactions with us. Michael Cox: Because they do produce, streptococcus produces lactic acid, Michael Cox: lactate, as a normal part of its metabolism. Michael Cox: It is technically in the larger group of lactic acid um producers of which lactobacillus

Michael Cox: is a relative so um yeah you can detect it we don't know again what it's doing Michael Cox: that's going to be a common theme i think when i'm talking about the microbiome i. Sheena Fraser: Know absolutely absolutely i yeah i did come across a paper um that looked at Sheena Fraser: the impact of some probiotics on lungs and um and lactobacillus helvetius or. Michael Cox: Health yeah. Sheena Fraser: Helvetius which is not one i'd heard of before um evidently has a positive effect

Sheena Fraser: on the lung microbiome by increasing iga in the mucosa which is sort of an early Sheena Fraser: defense against respiratory pathogens, Sheena Fraser: um which is interesting um but you know i don't know whether the you um i don't Sheena Fraser: know where you get helvetica's from. Michael Cox: No and it's really difficult because lots Michael Cox: of the ways we measure these things are not very good so so a lot of the sequencing Michael Cox: techniques that we have to use so you can you can isolate bacteria but we don't

Michael Cox: isolate all of them because you have to use a huge range of conditions to actually isolate them. Michael Cox: So we're always sort of sub-sampling when we try and grow something because Michael Cox: we will be missing a bunch of stuff. Michael Cox: So we use a lot of DNA sequencing techniques. Michael Cox: The issue with those is identifying the organism. Michael Cox: So firstly, knowing which one it is, because maybe we'll only get a genus name, Michael Cox: but we know that the impact to probiotics, we know that pathogenicity is definitely

Michael Cox: a strain or substrain level property. Michael Cox: So we're not accessing that information. We're just sort of, Michael Cox: we're finding the village. Michael Cox: We're not finding the address. Michael Cox: So there's that issue. The other one is that the sequencing techniques have Michael Cox: this property that they are relative abundance methods. They're not quantitative. Michael Cox: So on the whole, what you do is you sequence and it's a proportion that you see.

Michael Cox: If something increases in abundance, we don't know whether it's increasing itself Michael Cox: and everything else is staying at the same level. Michael Cox: Or it's increasing and we're pushing everything else out of the ability to sample it. Michael Cox: So that makes everything really difficult. So we can usually see if something Michael Cox: has increased in abundance. Michael Cox: We can't see decreases with this method. Michael Cox: So where that becomes particularly important for understanding interactions

Michael Cox: between organisms is that we can't see negative interactions. Michael Cox: People will assume them, Michael Cox: Because we think of it in competition. If something's increased and something Michael Cox: else has gone, we think, oh, they're in competition with each other. Michael Cox: But actually, the technique can't tell us that. Michael Cox: We need a real quantitative technique. Michael Cox: So if you're reading papers about this, what you'd like to see there is somebody Michael Cox: do a specific qPCR or a specific sort of isolation of those two organisms to

Michael Cox: confirm whether they're genuinely in competition with each other. Michael Cox: Or in fact it's just that that method hasn't been sensitive enough to detect Michael Cox: the change or lack of change in one of them. Michael Cox: So yeah, that sort of competition thing which has got to be essential to understanding Michael Cox: infection and protection against Michael Cox: infection is something we are not good at generally with this technique. Michael Cox: So we have to be quite careful.

Sheena Fraser: And I guess from that technique, we're sort of assuming function. Yeah, always. Sheena Fraser: Whereas, you know, now we should be looking at function a little bit more, Sheena Fraser: you know, rather than just considering who's there and how many of them are there. Sheena Fraser: You know, what are they actually doing and what are they producing? Sheena Fraser: So are there any studies on function of these organisms in the lungs? Michael Cox: So in the lungs, far fewer, because it's hard to look at function in situ.

Michael Cox: It's really interesting to me because this parallels all the questions we had Michael Cox: in environmental microbiology 20 years ago. Michael Cox: So we started by trying to like profiling what was there and then associating Michael Cox: that with measures in the environment. Michael Cox: So in the human sort of study, we're measuring what's there and associating Michael Cox: that often with disease. Michael Cox: Disease is really actually a far down the line process. Michael Cox: It's not what's actually happening.

Michael Cox: It's not what the organism is experiencing. It's not what the cells are experiencing. Michael Cox: It's the ultimate endpoint. Michael Cox: A lot of life has happened alongside that. Michael Cox: So those associations, I think, are going to be, you know, at the moment they're quite distant. Michael Cox: A lot of people measure lung function in microbiome studies. Michael Cox: Trying to find an organism or a group Michael Cox: of organisms that relates to lung function at Michael Cox: all usually it's negative however you know that doesn't mean it's not important

Michael Cox: um it means we're potentially measuring something so far distant from what it Michael Cox: is the processes that are actually going on um in vitro so you can look at function Michael Cox: of organisms we're quite good at sort of measuring. Michael Cox: You can use models to look at how virulent they are. Michael Cox: You can use models to look at whether there's interactions with the immune system in some way. Michael Cox: Those models are always a compromise. They're always something slightly different

Michael Cox: to what's going on in the human. Michael Cox: So one of the things I think lots of people in this field are trying to do at Michael Cox: the moment is to try to try and find good models to answer particular questions. Michael Cox: And that's everything from, Michael Cox: you know, just changing the media that you're growing the bacteria in to make Michael Cox: it look a bit more like an airway. Michael Cox: So literally adding some pig lung mucin Michael Cox: to that or pig stomach mucin to Michael Cox: your culture to see how it interacts with mucin to Michael Cox: models that are sort of organoids

Michael Cox: where you build up a 3D cell culture Michael Cox: where you start to see ciliated cells Michael Cox: that you would expect to see in the lungs as well that's so Michael Cox: intensive that you know adding bacteria Michael Cox: to that is a is a risky maneuver because you get it Michael Cox: wrong and you just you've ruined your cell culture as opposed to achieved something Michael Cox: in terms of understanding interaction but yeah it's it's what everybody is trying Michael Cox: to do at the moment um i'd love to do more stuff that's closer to the reality Michael Cox: of the lungs and and disease um and so would everybody else yeah.

Sheena Fraser: So i'm getting the impression here that it's not an easy subject that you're Sheena Fraser: studying here this is not this is not an easy field. Michael Cox: I don't I mean I it's sort of why I like microbiome because it's it's um as a as a topic it's, Michael Cox: because it's important. We know it's important. We know that there are direct Michael Cox: interactions with people. Michael Cox: We know it's probably going to relate to both health and disease, but it's so confounded. Michael Cox: There's so many things where maybe we're measuring the right thing, maybe we're not.

Michael Cox: Maybe it's related to this aspect of disease, maybe it isn't. Michael Cox: It's full of red herrings. Michael Cox: That actually makes it quite interesting to try and pick all that apart. Michael Cox: Um so so that's why i like it but yeah it's it's a bit messy okay. Sheena Fraser: Well let's talk about things that we can kind of. Michael Cox: Okay already. Sheena Fraser: Say about it so so let's talk about the influencers on the the lung microbiome Sheena Fraser: um i've got a list of things that i think are influencers.

Michael Cox: On microbiome let's. Sheena Fraser: Go through them and then you can tell me whether they are or they aren't. Michael Cox: It'll probably be maybe a lot of maybes but go on okay. Sheena Fraser: All right so first of all pollution. Michael Cox: I think probably yeah so so we Michael Cox: know that there's um so one Michael Cox: of the proxies we have for an influence on my a Michael Cox: microbial community is whether we see any impact on infection so if there's Michael Cox: more pollution about this probably you've got higher chances of getting infection

Michael Cox: we can probably anticipate therefore that there's an impact directly on the Michael Cox: microorganisms in the lungs. Michael Cox: People have shown that pollution and smoking can change how, Michael Cox: bacteria interact with lung cells so Michael Cox: it might make them a bit stickier might make them a bit Michael Cox: more pathogenic that changes their expression so yes Michael Cox: i would say pollution um does have Michael Cox: an impact there on the microbiome and quantifying it

Michael Cox: across all these organisms um because there's quite a few of them at any one Michael Cox: time in a population of people you're going to see a lot of difference there Michael Cox: in responses so there's a lot of other things that interact with that but yeah Michael Cox: for sure pollution i think is a good one and. Sheena Fraser: I guess there's lots of stuff in pollution that behaves differently. Michael Cox: Not one thing yeah one thing exactly because. Sheena Fraser: There's there's gases and there's metal heavy metals and there's particles. Michael Cox: And um.

Sheena Fraser: You know there's lots of different things there that will have slightly different Sheena Fraser: impacts as well on the lungs and the, and the microorganisms. Sheena Fraser: Um, but, but my, I would have thought that most of them are pro-inflammatory, um, Sheena Fraser: and, and creating some degree of inflammation in the lungs, Sheena Fraser: either through a direct mechanism on the Sheena Fraser: tissues or an indirect mechanism via the Sheena Fraser: microbes or the um or other other things that it's shifting in the community

Sheena Fraser: and in the environment yeah um you know disabling the cilia um the little hairs Sheena Fraser: um you know doing things like that that stops the the mucus from traveling up and down yeah. Michael Cox: So we know that that has an impact using sort of, Michael Cox: again, a sort of proxy in disease where cystic fibrosis, for example, Michael Cox: mucus is thicker, so the ciliary beat is less effective, and that leads to a Michael Cox: buildup of mucus, which gets infected.

Michael Cox: And there's a sort of related but quite different mechanism in another disease Michael Cox: called primary ciliary dystynesia, where there the mucus is normal, Michael Cox: but the cilia don't beat properly, so they're not shifting. Michael Cox: And there we see similar chronic infections, but actually slightly different Michael Cox: combination of organisms. Michael Cox: So I think that's kind of interesting how, you know, ecologically the environment Michael Cox: is a little bit different. Michael Cox: So those two things that aren't quite the same and therefore we see slightly different organisms.

Michael Cox: We're getting back to pollution as well. I think the other thing to remember Michael Cox: is that bacteria are biological entities as well. Michael Cox: So if there's something that's a bit toxic that's about, often those things Michael Cox: are sort of quite generally toxic or dangerous to living cells. Michael Cox: They will affect the organisms too. Michael Cox: So we did a population study a number of years ago. Michael Cox: So this is when I was based at Imperial College in collaboration with a big

Michael Cox: population study in the town of Busselton in Western Australia. Michael Cox: And there we looked at throat swabs, the back of the throat, Michael Cox: which is sort of a good overlap with what's in the lungs in healthy people. Michael Cox: So rather than doing hundreds of bronchoscopies across this town of Busselton, Michael Cox: we took throat swabs from an ongoing health study. Michael Cox: And there we saw a really clear relationship with smoking.

Michael Cox: So people who'd smoked longer Michael Cox: or a large amount or had Michael Cox: ever smoked and then quit had different combinations of organisms in their lungs Michael Cox: but the impact of smoking seemed to be that total numbers of bacteria were down Michael Cox: so you know there's there's reactive oxygen species in caused by cigarette smoking, Michael Cox: there's toxic compounds in cigarette smoke. Michael Cox: So they've had an impact on the bacteria. As well as causing inflammation,

Michael Cox: you've got fewer bacteria present in the lungs. Michael Cox: But interestingly, some of them survived a little better. So everything was Michael Cox: down, but the streptococci were down less. Michael Cox: So in terms of the composition, you see the skew to everything becoming streptococcus. Michael Cox: Now, if streptococcus has a particular function, and now it finds itself freed Michael Cox: from all these other organisms and in a more inflamed environment. Michael Cox: What happens to its function there?

Michael Cox: Is it still functioning as it was when it was a commensal? Is it now doing something Michael Cox: else which may be cycling and helping to increase the inflammation that you have there anyway? Michael Cox: Interestingly we think we saw this, Michael Cox: was you know we didn't quite have the numbers to be certain about this but what Michael Cox: we thought we saw as well was that as people stopped smoking,

Michael Cox: the lung microbiome returned to normal. So it started looking like a healthy one. Michael Cox: And the longer ago you quit, the closer to what we usually see in healthy non-smokers was the case. Michael Cox: So it's the same as, you know, stopping smoking has an impact, Michael Cox: a positive impact on your lung microbiome too. Sheena Fraser: Did you see a point where it normalized or was that different for different people? Michael Cox: So this is this is where it gets because we didn't quite

Michael Cox: have the the sort of range in numbers of age Michael Cox: or time since people had stopped smoking to be sure about that um so length Michael Cox: of time really hard to say and probably quite inaccurate but five to ten years Michael Cox: you know that kind of range of time but i think would be reasonable so. Sheena Fraser: We know now that pollution and smoking are definite impactors. Yes. What about vaping? Michael Cox: Vaping, what is this space? So we're just starting with collaborators,

Michael Cox: a project around vaping. Michael Cox: So Dr. Aaron Scott at the University of Birmingham is an immunologist and he's Michael Cox: looking at inflammation in the context of using either vaping or nicotine patches Michael Cox: to help you stop smoking. Michael Cox: So our contribution to that study will be looking at the microbiome in that Michael Cox: context as well I'd imagine it probably has an impact I'd imagine it was probably Michael Cox: a little bit different to cigarette smoke because it's a different range of

Michael Cox: compounds that you're being exposed to, Michael Cox: I think the thing to remember with vaping as well is how variable it is because Michael Cox: it's not regulated sort of market in the same way as cigarettes and smoking. Michael Cox: And there's a lot of flavour compounds that go in there, a big variety of them. Michael Cox: So what happens to them when they're heated, how those interact with our own Michael Cox: cells, all the bacterial cells, the microbiome that's there,

Michael Cox: is going to be unpredictable. Sheena Fraser: Yeah, and I think I've read one paper that has looked, Sheena Fraser: at the impact of vaping already and, and found that those flavors and the, Sheena Fraser: um, yeah, the, the, the flavors when they're, um, initiated into lungs do create Sheena Fraser: some inflammation as you would imagine. Michael Cox: Yeah. Sheena Fraser: Um, but the other thing is the heating element in the, in the vape, um, Sheena Fraser: because the heating element actually gives off a whole load of, um,

Sheena Fraser: metals and you inhale a load of metals and, And they've actually found quite Sheena Fraser: a lot of different metals in the lungs, chromium and tin and aluminium and all sorts of things. Sheena Fraser: And a lot of these metals are actually quite inflammatory as well. Sheena Fraser: Aluminium is very inflammatory in the lungs. Sheena Fraser: So that's an interesting one as well. And just the heat, I think, from vaping. Sheena Fraser: Because heat in its own right can create inflammation. but also the DNA damage in cells, can't it?

Michael Cox: Yeah, it's such a difficult topic because one of the things I think concerns Michael Cox: me as well is the age of people vaping is also much, much younger. Michael Cox: And what we're actually talking about, there are sort of developing lungs, Michael Cox: lungs that are still developing and causing damage to them early on, Michael Cox: is likely to store up issues for later.

Michael Cox: As a smoking cessation tool, it's a little bit more nuanced because there you're Michael Cox: talking about, is it better than... Michael Cox: Cigarette smoke and it's a relative thing. So if it's helping people to stop Michael Cox: smoking and while it might still be damaging, it's better than smoking, Michael Cox: it's trying to measure a sort of relative risk there. Michael Cox: But I think it's probably safe to say if you've managed to stop smoking by vaping, Michael Cox: it would probably be good to be trying to stop vaping after that as well because

Michael Cox: nicotine in and of itself is is not a great thing to be to be getting into your body. Sheena Fraser: Yeah nicotine on an adolescent brain as Sheena Fraser: well is very harmful it can cause behavioral problems Sheena Fraser: and mood problems um interestingly um Sheena Fraser: i mean i i looked up 10 of our adolescent are vaping now and i and i wonder Sheena Fraser: actually if that's even higher in my my local kids school as well because uh Sheena Fraser: talking to my own children about how many kids in their year are vaping.

Sheena Fraser: And actually, you're more likely to smoke if you start off vaping. Michael Cox: Yeah. Sheena Fraser: Yeah. As much as it's been used as a way of stopping smoking, Sheena Fraser: it actually may initiate you towards smoking as well, which is not wonderful. Sheena Fraser: Yeah, I have my concerns about vaping. And, you know, I've seen young patients Sheena Fraser: coming along with serious vaping habits, equivalent to, you know, 20 cigarettes a day. Sheena Fraser: And whilst I agree, they're probably safer than cigarettes.

Sheena Fraser: There's still a risk there. And I think that really needs to be ironed out. Sheena Fraser: And I think our children need to be kept away from vapes as much as possible Sheena Fraser: to preserve their developing lungs. Michael Cox: Yeah, there's a difference there, isn't there, between somebody who's maybe Michael Cox: in their 50s and has smoked their entire life and needs to get off cigarettes for their lung health. Michael Cox: That's different to a sort of 12, 13, 14 year olds with growing,

Michael Cox: developing lungs who is starting vaping and hasn't tried cigarettes yet. Michael Cox: They're two very different usage cases and two very different sort of outcomes probably as well. Sheena Fraser: That's smoking, vaping, pollution. What about volatile organic compounds? Sheena Fraser: Have you come up with that? Have you used much Vox? Michael Cox: I mean, so not in the context of the lung microbiome very much, to be honest. Michael Cox: I think what we're often talking about with these things is lung inflammation.

Michael Cox: And that's going to be key for understanding the interaction with the microbiome. Michael Cox: Because I think one thing, we're always looking at chicken and egg with a gut Michael Cox: microbiome, with lung microbiome as well. What's causal? Michael Cox: And we know that there's some pathogens that you can spread around and they Michael Cox: will infect you and they will cause inflammation. They'll cause infection,

Michael Cox: they'll cause inflammation. Michael Cox: So, you know, there's examples of viruses like that. There's examples of bacteria Michael Cox: like that. So one of the streptococci is streptococcus pneumoniae. Michael Cox: We can carry it, but also it can cause pneumonia. Michael Cox: However, there are other situations where we might have some kind of inflammation Michael Cox: caused by something else, whether that's external, like pollution, Michael Cox: volatile organic compounds or whatever. Michael Cox: And then the bacteria already in your lungs are in a different environment to

Michael Cox: what they were in before. Michael Cox: So we see some of the shifts in communities that we see in microbiome studies Michael Cox: might just simply be a population of bacteria who are having to live now in Michael Cox: a much more inflammatory environment. Michael Cox: So they're dealing with a lot more immune system than they're used to dealing Michael Cox: with on your average day. Michael Cox: So their response might be to just disappear and die, or it might be to become Michael Cox: more actively pro-inflammatory as well. Michael Cox: So anything I think that causes inflammations in the lungs is going to have

Michael Cox: an impact on your respiratory microbiome. Michael Cox: Whether those changes are then part of the pathology of what then happens afterwards... Michael Cox: It's hard to say. So volatile organic compounds, particularly bad for lungs. Michael Cox: It's probably not a good thing to be inhaling all the time. Sheena Fraser: We should probably say what they are, actually. Michael Cox: Go for it. There's a bunch of, there's all sorts of different things. Michael Cox: It's a huge category of chemical compounds. Sheena Fraser: So they're chemicals that vaporize at room temperature.

Sheena Fraser: So the sort of things that contain your Vox are your spray deodorants and your spray cleaning. Sheena Fraser: Products, furniture, floor polishes, oven cleaners, detergents, Sheena Fraser: dishwashers, dishwashing liquids. Sheena Fraser: And these compounds, as you say, they're totally variable. Sheena Fraser: And they've studied, there have been some studies on hairdressers that use more. Sheena Fraser: So, for example, hairdressers that deal with Afro hair more,

Sheena Fraser: they use more of these compounds to straighten the hair. Sheena Fraser: And they did have a difference in their lung microbiome, presumably through Sheena Fraser: sputum samples, than the hairdressers that didn't use quite so many of those compounds. Sheena Fraser: And I think VOX's or exposure to VOX have been linked to lung cancer that I'm Sheena Fraser: aware of. And there's actually, there's a few studies on that now.

Sheena Fraser: And women especially seem to be more vulnerable to the effect of Vox on the lungs. Sheena Fraser: From a study, there was a study that was written in 2018, Long-Term Effects Sheena Fraser: of Cleaning on the Lungs. Sheena Fraser: And it looked at a whole bunch of 6,000 adults between 1992 and 1994. Sheena Fraser: And they looked at people who clean for a living and people who clean domestically. Sheena Fraser: And women especially who clean for a living had a lot more disruption to their

Sheena Fraser: microbiome and they looked at levels of inflammation. Sheena Fraser: I think they're measuring FENO, is that right? Michael Cox: Oh yes, I've heard of that one. So this is the thing, so I'm not a sort of respiratory Michael Cox: doctor And so this sort of heads into the realm of occupational exposure and Michael Cox: those kind of respiratory diseases. Michael Cox: So they're often also less well studied Michael Cox: than, you know, either the chronic infective kind of lung diseases.

Michael Cox: So these sort of exposure diseases, because maybe they, you know, Michael Cox: they're harder to spot. So hairdressers, for example, you know, Michael Cox: it's a more dispersed group of people. Michael Cox: They're not working for one organization and trying to even noticing that they Michael Cox: have particular sort of impacts on their respiratory health is hard work. Sheena Fraser: In this world that we're living in we're obviously surrounded by these chemicals

Sheena Fraser: aren't we it's very hard to avoid them they're they're in our lives in you know Sheena Fraser: in so many different ways so so it would be good to get more research into this i think. Michael Cox: So yeah for. Sheena Fraser: Sure and to get more understanding of you know the harms from these things because Sheena Fraser: you know we need to know if we are doing ourselves harms with our once-a-week clean, Sheena Fraser: or if we should be switching to less harmful things,

Sheena Fraser: and liquid preparations rather than spray preparations, what's the risk? Sheena Fraser: If we're using deodorant, should we use liquid or solid deodorant, or should we use spray? Michael Cox: Should we be rolling on? Sheena Fraser: And so I do worry about the impact of these chemicals on the lungs, Sheena Fraser: and it makes a lot lot of sense from the reading I've done into aluminium and Sheena Fraser: into various different chemicals that are in these products that it would be Sheena Fraser: creating inflammation there.

Sheena Fraser: So I think this would be, you know, good to know a little bit more about. Sheena Fraser: So let me know if you know anybody that's investigating books, Sheena Fraser: because, you know, you're the guy who's going to find out. Michael Cox: I think the interesting thing there around microbiome, though, Michael Cox: is like, what would the solution be? Michael Cox: Is that a microbiome solution that we would be coming up with for that kind of thing? Michael Cox: But actually, you know, it's the solution there would be changing the way we

Michael Cox: clean, changing the cleaning products, not a sort of microbiome intervention. Michael Cox: Maybe the microbiome is playing a part, but actually the solution there is probably Michael Cox: not a microbiome-based solution. And that's interesting across the field, Michael Cox: I think, as well, because you see... Michael Cox: You see some people suggesting sometimes interventions that are microbiome-based, Michael Cox: but for things that actually we can impact in different ways. Michael Cox: And I'm in favor of choosing the right intervention there.

Michael Cox: So dietary stuff, for example, sometimes people reach for a probiotic or a live biotherapeutic. Michael Cox: And you're like, well, maybe, have we tested this against eating a banana once a day? Michael Cox: You know, improving your fiber intake or doing the sort of boring kind of five-a-day Michael Cox: interventions rather than necessarily going straight to a probiotic as your Michael Cox: first line of things to do. Sheena Fraser: Okay, well, you're moving on to diet now. So that was one of my next things.

Sheena Fraser: How does diet influence your lung microbiome? Michael Cox: I have lovely occasional arguments. So we have a really famous microbiome researcher Michael Cox: at Birmingham, Professor Lindsay Hall. Michael Cox: So she works on the infant gut microbiome. Michael Cox: And obviously, and particularly sort of mother and baby pairs and preterm birth Michael Cox: and things like that and how that relates to particularly bifida bacteria. Michael Cox: But we have a semi-regular conversation about dietary impact on the lung microbiome.

Michael Cox: And she's like, yes, of course, there's going to be a massive impact. Michael Cox: And I'm like, no, there definitely won't be. Michael Cox: And probably the reality is somewhere between the two of those things. Michael Cox: So I think the thing to remember is timescale and location of stuff. Michael Cox: So diet can have systemic effect. Michael Cox: But the important part of the interaction with the lung is that there are microorganisms Michael Cox: right there next to those cells.

Michael Cox: And we're always thinking, so gut microbiome focus, it influences the whole body. Michael Cox: It's like, yes, but these organisms are right there next to these immune cells, Michael Cox: being sampled by these immune cells, interacting directly with the epithelium. Michael Cox: Gut microbiome is further away. It's in a different compartment. Michael Cox: It's a different composition. So to have an impact there, Michael Cox: those organisms have to be churning out stuff that goes through a lot of filtering Michael Cox: into the bloodstream around the body, then it's a more distal effect.

Michael Cox: So what we're looking at there really is time, I think. Michael Cox: So in shorter timescales, in the timescales of sort of catching an infection, Michael Cox: being exposed to some pollution or something like that, local processes are Michael Cox: going to be super important. Michael Cox: The timescale of sort of a life or years or those kinds of things, Michael Cox: over the period of time where you might affect a change in your diet.

Michael Cox: Then probably that is going to have some sort of Michael Cox: systemic impact as well so so she and Michael Cox: i sort of have this conversation regularly and i Michael Cox: think it i think really what we're talking about is time Michael Cox: scale there so if you change your diet probably the Michael Cox: impact is not going to be anything immediate um if you change your diet in such Michael Cox: a way that um you change your weight you change your lifestyle then maybe longer Michael Cox: term we will see those things those studies haven't been done because they're Michael Cox: hard to do in the gut let alone they.

Sheena Fraser: Tend to be epidemiological so they tend to be looking at again correlations Sheena Fraser: don't they so the so people that eat more than five a day of fruits and vegetables um. Michael Cox: Well done then yeah tend to have lower. Sheena Fraser: They tend to have lower rates of asthma for. Michael Cox: Example or crpd yeah um. Sheena Fraser: And i you know i i've always thought that it did play a role um And personally, Sheena Fraser: because I had two grandmothers who smoked for 50 years, neither of which got COPD. Sheena Fraser: And they had a lot of plants in their diet. And okay, they did enough exercise and things as well.

Sheena Fraser: But I often thought that their lifestyle played a role in that. Sheena Fraser: And that is very anecdotal. But I've actually used that process with patients Sheena Fraser: and got them on higher fiber diets. Sheena Fraser: And what I've noticed is my COPD patients have particularly low fiber diets. Sheena Fraser: When they're diagnosed. And I put them on a much higher fiber diet. Sheena Fraser: And the last chat that I did, you know, we don't have a lot of COPDs in our Sheena Fraser: practice, but we had a guy who had quite severe COPD. Sheena Fraser: This was about eight years ago.

Sheena Fraser: And, um, he, he came to me and he had a low fiber diet, not doing very much exercise. Sheena Fraser: And I got him to adopt a high fiber diet and exercise really, really regularly. Sheena Fraser: So it's, you know, it's a cumulative, it's, it's a few different things that were changing. Sheena Fraser: Um, but in that time, since in that eight years, instead of nose diving, Sheena Fraser: like most of my COPD patients had done in the past, um, he's actually remained Sheena Fraser: incredibly well and fit and had one infection in that time that I'm aware of.

Sheena Fraser: So he's remained very, very fit and healthy and not got the number of infections Sheena Fraser: that I was expecting that he would get compared to other COPD patients. Sheena Fraser: And the other thing, the other little bit of evidence that I see as a doctor Sheena Fraser: is the oral microgram and the importance. Sheena Fraser: So whilst you say that diet is going to have that sort of slightly longer effect, Sheena Fraser: you know, it's going to take longer for it to impact coming from the gut. Sheena Fraser: The oral microbiome is going to change quite rapidly with diet change,

Sheena Fraser: isn't it? And the oral microbiome is going to impact on the lung. Sheena Fraser: It's the source of organisms. Michael Cox: Yeah, 100%. It's super, it's so difficult and it's really interesting because... Michael Cox: It's so hard in a human to make one change because you're always, Michael Cox: you know, so if somebody's improving their diet, then maybe they're feeling a bit better. Michael Cox: They get out a bit more and then exercise becomes an impact or even it turns Michael Cox: out that they start running in a field and they're getting a lot more hay fever

Michael Cox: and it goes in the other way or, you know, all this kind of stuff. Michael Cox: Oral microbiome for sure is linked to Michael Cox: things like copd so um you Michael Cox: know improved uh dental care Michael Cox: um you've got fewer less Michael Cox: plaque less uh organisms like Michael Cox: that sort of heading down into your lungs so there does seem Michael Cox: to be a relationship there um the the Michael Cox: cardiac doctors will probably say don't brush your Michael Cox: teeth too much because there's another link between

Michael Cox: sort of endocarditis and and sort Michael Cox: of heart health and brushing your Michael Cox: teeth too much or doing too much flossing and removing this stuff which goes Michael Cox: into your body and bloodstream and can link to link to heart disease in that Michael Cox: way so yeah it's super complicated particularly when we start talking about Michael Cox: a human and their life but but you know. Sheena Fraser: And I do wonder if those lactobacilli and nice milk-fermented foods and things

Sheena Fraser: are going to also benefit the lungs just through the effect on the immune system. Michael Cox: It is funny. So lactobacilli is sort of falling out of favor in the gut space as well. Michael Cox: So people like the bifida bacteria are what people are sort of going after. Michael Cox: But there's trends around this. Michael Cox: At the moment, we don't even know whether the ones that you find in the lungs Michael Cox: are the same species as the ones that we have in the guts.

Michael Cox: So, again, at the moment, we're talking about a distal effect of those lactobacilli, Michael Cox: even if there is one at all. Michael Cox: And trials of probiotics are sort of fraught with as many more failures than Michael Cox: there are sort of success stories. Michael Cox: It would be lovely to see some interventions in the long space that, Michael Cox: acknowledge the existence of a lung microbiome to start with and then maybe

Michael Cox: start to utilize it as a real tool for helping us with our health. Michael Cox: I think that's where I'd like to see things go, but at the moment we're quite far off that. Sheena Fraser: Well, as microbiome medics, we don't push people towards probiotics very often, Sheena Fraser: but we would push people towards a nice, healthy diet with fermented foods. Michael Cox: It's the banana. I think it's the banana. Sheena Fraser: Fermented foods regularly. And the Sonnenbergs in the US have really shown the

Sheena Fraser: impact of fermented foods on the gut and how beneficial that is. Sheena Fraser: So we haven't touched on exercise in the lungs. And I think that's a really important area. Sheena Fraser: So tell me about exercise in the lungs. Michael Cox: So it's not something, I think, again, I'm sort of thinking mostly about a sort of proxy here, Michael Cox: which is respiratory physiotherapy and shifting stuff up and out of the lungs Michael Cox: if you have a lung disease. Michael Cox: Certainly that's been shown to have a really positive impact in cystic fibrosis.

Michael Cox: And it's part of normal therapy there for people with cystic fibrosis. Michael Cox: If you can improve your sort of lung health in general, and exercise is one Michael Cox: way to do that, then probably it's going to help, Michael Cox: Prevention is a really strong word, but certainly improving your risk, Michael Cox: I think. Again, we'll probably see that at the population level. Michael Cox: Really hard to say what it's doing at an individual level mechanistically in

Michael Cox: terms of lung microbiome. Michael Cox: But I think numbers, you know, fewer numbers, if you've got an increase compared Michael Cox: to normal, is probably a good thing. Sheena Fraser: Yeah, as you say, there's probably so many different mechanisms by which exercise benefits. Sheena Fraser: Microbes yeah um and you know it depends whether you're exercising in nature Sheena Fraser: or exercising uh you know in a gym environment again you're going to pick up Sheena Fraser: different microbes and things aren't you and yeah and you're going to have different Sheena Fraser: impacts from fresh air and and you know if there's.

Michael Cox: Somebody in the corner who's who's you know who's who happens to have rsv or Michael Cox: covid at that particular time then you know that's going to outweigh your your Michael Cox: the impact of your uh of your uh of your particular exercise regimen on that. Sheena Fraser: Day yeah but hopefully if you're exercising hard then you know hopefully you're Sheena Fraser: stimulating your immune system enough to to be able to tackle those those viruses Sheena Fraser: that are probably in the air all the time anyway yeah yeah yeah,

Sheena Fraser: um okay so so exercise Sheena Fraser: good and and we know from epidemiological studies Sheena Fraser: that exercise really helps with um you Sheena Fraser: know the reducing your likelihood of asthma COPDs all these all these long chronic Sheena Fraser: lung conditions and and of course helping reduce your chance of more serious Sheena Fraser: lung conditions like um lung cancer yeah so so they're all beneficial but there's there I. Michael Cox: Think we have to remember there, sorry to interrupt, we do have to remember

Michael Cox: there the genetic components to these diseases as well. Michael Cox: Because sometimes I think we sort of encourage groups of people to do things, Michael Cox: but actually it's very hard for them because they have a genetic predisposition to a particular thing. Michael Cox: So asthma has a genetic component as well as an environmental. Michael Cox: COPD, there's people with alpha-1 antitripsin. So I'm a carrier of that. Michael Cox: And that gives you a much higher chance of getting COPD.

Michael Cox: So exercise is a component for sure, but it's only going to take some people so far of the way. Sheena Fraser: Of course. And some genetic conditions are, your genes are your fate. Sheena Fraser: With the case of cystic fibrosis, of course, you can't turn that around. Sheena Fraser: But for a lot of of genetic disorders, genes can flip and genes can change. Sheena Fraser: And epigenetics is a very interesting thing where, you know,

Sheena Fraser: your lifestyle actually can massively influence your genes and you can turn Sheena Fraser: on and off genes through, you know, changing your lifestyle quite dramatically. Sheena Fraser: And, you know, in lifestyle medicine, we learn a lot about epigenetics and how Sheena Fraser: we can influence our genes through diet and lifestyle and sleep and exercise Sheena Fraser: and all of these things. So there's hope for... Sheena Fraser: The majority of us. But of course, you know, if you have a serious genetic disorder,

Sheena Fraser: then unfortunately we can't often flip those genetics for you. Sheena Fraser: So yes, it depends on the genetic disorder, doesn't it? Sheena Fraser: Okay. All right. Interesting. So if you have one message, Mike, Sheena Fraser: before we go about the lung microbiome that you want to get across to people. Sheena Fraser: You want to spike their interest and obviously get them thinking about the lung Sheena Fraser: microbiome. What will you say?

Michael Cox: That's a challenge. Michael Cox: What this always makes me think of is slightly bored students in my lectures. Michael Cox: And I think, so how do we get them engaged? Michael Cox: I think the thing with the lung microbiome is that it is real. Michael Cox: It's changes with disease and we really need to understand it because there's Michael Cox: real potential there to have some kind of intervention that makes conditions last less time.

Michael Cox: I would hope that actually we get some ways of predicting when we need to intervene Michael Cox: through understanding the lung microbiome. That's where I'd really like to go, I think. Michael Cox: So some sort of meaningful intervention and also understanding what interventions Michael Cox: aren't worthwhile as well because again, Michael Cox: you know, interfering too much can be an issue too so that's what I'm interested Michael Cox: in in particular I think in this space and I'm hoping my sheer enthusiasm will

Michael Cox: carry other people along with me because I'm not sure whether the message does or not. Sheena Fraser: Well, do you know, the interest in microbiomes, human microbiomes in general, Sheena Fraser: is just climbing constantly. Sheena Fraser: You know, I'm just, you know, I'm even seeing it in my primary and secondary care colleagues now, Sheena Fraser: that more and more of them are taking note of microbiome science and want to Sheena Fraser: learn about the gut microbiome and other human microbiomes. Sheena Fraser: So, you know, I think the interest is starting to peak now and we just need

Sheena Fraser: to keep people's enthusiasm up and hopefully, Sheena Fraser: you know, more interest, you know, instead of just thinking of the lungs in Sheena Fraser: terms of physiology and, you know, in terms of the diseases of the lungs. Sheena Fraser: Let's think a little bit more deeply and consider the microbes as well and think Sheena Fraser: about them and how there's this other element here that could be changing the Sheena Fraser: dynamics of this important organ. Sheena Fraser: And we all should be aware of these little organisms and how they're impacting our health.

Sheena Fraser: And we need to learn more, as you say, as to why that is. Sheena Fraser: So thank you so much for coming on today. Sheena Fraser: Good luck with all your research what's next for you Mike? Michael Cox: I think we're trying to understand what the bacteria in our lungs are eating Michael Cox: because they've got to eat something and then we can tweak that and then we've Michael Cox: got a little tool to manipulate the communities so that's one of the next things Michael Cox: we're looking at Brilliant. Sheena Fraser: Right well keep me informed keep me updated Take care, nice to see you Bye bye.

Intro and Outro: Thank you so much for listening to this episode of Microbiomedics Podcast. Intro and Outro: We really hope you enjoy the content and we welcome your feedback. Intro and Outro: We'd love to hear any suggestions you might have for microbiome topics that Intro and Outro: you'd like us to cover and we also appreciate listeners' questions and we'll Intro and Outro: endeavour to answer them in the next podcast.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Our Testing Journey: Dr Alena Pribyl on analysis of the human gut microbiome at Microba Life Sciences

    Oct 16, 20261 hr 5 minAudio

    Have you ever wondered what microbiome testing looks like? In this episode, co-hosts Dr Siobhan McCormack and Dr Sheena Fraser chat to guest Dr Alena Pribyl from Microba Life Sciences, after sending off their poo...

    Credit the people on this episode

  2. Defining Gut Health: Moving Beyond the Buzzwords with Prof. Maria Marco

    Jul 15, 202653 minAudio

    While "gut health" is a ubiquitous buzzword in the wellness industry, it has historically lacked a clear scientific definition. In this episode, host Dr. Siobhan McCormack sits down with world-renowned expert Professor...

    Credit the people on this episode

  3. Eat to Sleep: The Power of Chrononutrition and Circadian Rhythms

    Jun 17, 20261 hr 8 minAudio

    While we often think of sleep and diet as separate pillars of health, our internal biological clocks and gut microbiome intricately connect them both. In this episode, co-hosts Dr. Siobhan McCormack and Dr. Sheena...

    Credit the people on this episode

  4. Biological Liquid Gold: Why Breast Milk Isn't Actually for the Baby (It's for the Microbes) with Prof. Chris Stewart

    Apr 15, 20261 hr 40 minAudio

    Join Dr. Siobhan McCormack as she welcomes one of the top early-life microbiome scientists in the field, Professor Chris Stewart. Discover the origins of your gut microbiome, the biological superpowers of breast milk,...

    Credit the people on this episode

  5. From Superyacht Chef to Microbiome Scientist: Dr. Emily Leeming on the "Cinderella Nutrient" Fibre

    Mar 18, 20261 hr 6 minAudio

    Join Dr. Siobhan McCormack and the "fibre-fabulous" Dr. Emily Leeming, a former superyacht chef turned King's College London microbiome scientist and registered dietitian. Discover why fibre is the overlooked...

    Credit the people on this episode